Recent advances in the study of cell cycle control have suggested the existence of a universal control mechanism common to all eukaryotic cells, regulating the onset of mitosis (Nurse, 1992) . Normal cellular growth is controlled by the cell cycle and malignancy arises from derangements of such proliferation.
The extent to which cells escape from normal cell cycle control may reflect their degree of malignancy. It is likely that the association between a high proliferation rate and the degree of tumour invasiveness is a general feature of human solid tumours. However, a high proliferation rate is more likely to be a variable associated with rather than the cause of biological aggressiveness. Departure from normal cell cycle control may be detectable by measurement of abnormalities of the expression of antigens associated with cell cycle control. Such antigens include proliferating cell nuclear antigen (PCNA).
PCNA is an evolutionarily highly conserved acidic protein of 36 kDa, which was independently discovered by Miyachi et al. (1978) as PCNA and by Bravo and Celhs (1980) as cycin. It has more recently been identified as an essential accessory factor to the delta polymerase, which is required for both leading strand DNA replication and DNA repair (Bravo et al., 1987; Prehlich et al., 1987; Toschi and Bravo, 1988; Shivji et al., 1992) . It is necessary for DNA replication, DNA repair, cell cycle progression, cellular proliferation and is expressed in late G1-S-phase. PCNA therefore accumulates in cycling cells, and thus in normal tissue PCNA immunolocalisation can be used as an index of the degree of cell proliferation as staining is confined to proliferating cells (Sarraf et al., 1991) . In malignant tissue a high level of PCNA immunostaining may identify aggressive tumours and provide a guide to the proliferation rate of the tumour (Hall et al., 1990 (Kaplan & Meier, 1958) . The data were divided into tertiles and, using these as ordered categories, the log-rank trend test was performed. of cases and scored positive or negative. Ten cases were excluded as no staining was visible. This appeared to be due to technical failure: because of the poor quality of the archival material heat had to be used to assist adherence of the section to the glass slide, which resulted in no staining.
PCNA immunostaining is illustrated in Figure la and b. The characteristics of the study group as compared with the whole group are outlined in Table I . including the proportion of patients in the study group and whole group who were suitable for randomisation and the histological grade and subgroup.
A lack of concordance was seen between mitotic index and PCIO LI. The mitotic index ranged from 0.005% to 5%. Cell cycle times for tumours are thought to be of the order of 8-33 h (Bresciani. 1965; Frankfurt. 1967) Figure 2 . Overall survival for the study group correlated inversely with PCIO LI (see Figure 3) . Of the 37 patients who underwent good debulking surgery (<2cm residual disease), 20 were randomised and received additional therapy (ten to carboplatin and ten to radiotherapy). Of the remaining 17, five achieved complete remission, nine suffered disease progression, two had adhesions preventing assessment and one died during chemotherapy. In this group a low PCIO value (the lower tertile was 0-36.5%) correlated with improved survival (see Figure   4 ) (log-rank trend test for survival, jx = 5.75, P= 0.017).
Survival by PCIO LI for stage 3 well-debulked patients only is shown in Figure 5 Rapid tumour growth rate is generally associated with poor prognosis (Tubiana and Courdi, 1989) . Derangements of cell cycle control and hence proliferation may result in the development of malignancy, and the degree of malignancy may be related to the extent to which cells escape from this control. Such escape may be detectable by measuring alteration in expression of genes associated with the cell cycle including p53, Rb and the PCNA gene (De Caprio et al., 1989; Hall et al., 1990; Levine et al., 1991) .
The PCNA gene is necessary for DNA replication, DNA repair, cell cycle progression and cellular proliferation. Exposure of cells to antisense oligodeoxynucleotides to PCNA results in complete cessation of DNA synthesis and cellular proliferation (Jaskulski et al., 1988; Liu et al., 1989 A method of measuring tumour cell proliferation which can be performed on archival, paraffin-embedded material has many advantages. Studies on a range of malignancies have shown that PCNA LI correlates with other means of measuring tumour proliferation such as flow cytometnrc analysis of S-phase fraction, tritiated thymidine labelling index (LI), bromodeoxyuridine (BrdU) identified labelling index and Ki67 labelling index (Dawson et al., 1990; Allegranza et al., 1991) . In most studies PCNA LI values are higher than tritated thymidine LI and BrdU LI and S-phase fractions calculated from flow cytometric DNA histograms (Garcia et al., 1989) . This may, in part, be explained by the fact that PCNA is expressed during GI, S, G2 and M-phases of the cell cycle and not just restricted to S-phase.
Comparisons have been made between PCNA immunostaining and Ki-67 as a means of assessing proliferative activity (Louis et al., 1991; van Dierendock et al., 1991) . Not all studies show a correlation between the two methods and a suggested explanation is that PCNA expression may be deregulated in malignancy and expressed persistently in some cells which are not actively dividing (Rosa et al., 1992 (American Cancer Society, 1986) . This study shows that there is a trend towards high PC1O values in patients with poor survival and, importantly, in those patients who had undergone optimal debulking surgery (<2 cm residual disease), it selects out a subgroup who have double the median survival (44 as compared with 22 months). This suggests the need for a prospective randomised trial to establish the clinical significance of this prognostic marker. A knowledge of the proliferative activity of tumours may be useful in the evaluation of prognosis and provide a means of selecting patients for appropriate therapy. Ultimately it may be appropnrate to select patients for more intensive treatment regimens -for instance maintenance cytokine therapy or radiolabelled monoclonal antibody therapy -on the basis of the biology and malignant potential of disease as determined by quantitation of proliferation, measured in this way.
